Eton Pharmaceuticals (ETON) Income towards Parent Company: 2019-2025
Historic Income towards Parent Company for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to -$1.9 million.
- Eton Pharmaceuticals' Income towards Parent Company fell 407.34% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 21.91%. This contributed to the annual value of -$3.8 million for FY2024, which is 308.44% down from last year.
- As of Q3 2025, Eton Pharmaceuticals' Income towards Parent Company stood at -$1.9 million, which was up 25.45% from -$2.6 million recorded in Q2 2025.
- Eton Pharmaceuticals' Income towards Parent Company's 5-year high stood at $5.1 million during Q1 2021, with a 5-year trough of -$6.1 million in Q3 2021.
- Its 3-year average for Income towards Parent Company is -$985,727, with a median of -$1.6 million in 2025.
- As far as peak fluctuations go, Eton Pharmaceuticals' Income towards Parent Company skyrocketed by 392.62% in 2023, and later tumbled by 407.34% in 2025.
- Eton Pharmaceuticals' Income towards Parent Company (Quarterly) stood at $1.0 million in 2021, then decreased by 12.22% to $912,000 in 2022, then plummeted by 347.37% to -$2.3 million in 2023, then surged by 73.49% to -$598,000 in 2024, then slumped by 407.34% to -$1.9 million in 2025.
- Its last three reported values are -$1.9 million in Q3 2025, -$2.6 million for Q2 2025, and -$1.6 million during Q1 2025.